Eledon Pharmaceuticals (ELDN) Expected to Release Quarterly Earnings on Friday

Eledon Pharmaceuticals (NASDAQ:ELDN) is expected to be announcing its Q3 2026 results on Friday, November 13th. Analysts expect Eledon Pharmaceuticals to announce earnings of ($0.20) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 19, 2026 at 4:00 PM ET.

Eledon Pharmaceuticals (NASDAQ:ELDN) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.11).

Eledon Pharmaceuticals Stock Down 3.8%

Shares of NASDAQ:ELDN opened at $2.76 on Wednesday. Eledon Pharmaceuticals has a 52-week low of $1.35 and a 52-week high of $4.49. The stock’s fifty day simple moving average is $2.59 and its 200-day simple moving average is $3.11. The company has a market capitalization of $224.28 million, a P/E ratio of -3.03 and a beta of 0.95.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on ELDN shares. Weiss Ratings upgraded Eledon Pharmaceuticals from a “sell (d-)” rating to a “sell (d)” rating in a research report on Monday. Rodman & Renshaw initiated coverage on shares of Eledon Pharmaceuticals in a report on Tuesday, July 21st. They issued a “buy” rating and a $12.00 target price on the stock. Finally, Wall Street Zen cut shares of Eledon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Sunday, August 23rd. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $10.00.

Eledon Pharmaceuticals Company Profile

Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies that selectively modulate the immune system for patients with life-threatening diseases. The company’s research is centered on conditions involving immune activation, including organ transplantation, autoimmune disorders and other inflammatory diseases. Eledon’s lead product candidate is tegoprubart, a monoclonal antibody designed to block CD40 ligand, a protein involved in immune-system signaling.